Francis Knuettel II sold (to issuer) 13,947 shares of PTHS
Francis Knuettel II (CFO, Treas & Secty) sold (to issuer) 13,947 shares of Pelthos Therapeutics Inc. (PTHS) on 2026-05-22.
How this was made
The 30-second read
Why it matters
The filing reports an officer/direct sale to the issuer (code D) dated 2026-05-22, filed 2026-05-26; it does not provide transaction price or stated rationale.
Market read
Traders may monitor for insider activity, but this specific disclosure lacks fundamental details and is unlikely to drive a sustained repricing.
What to watch
No disclosed price/value and no 10b5-1 plan; the holdings after transaction (19,525) suggest the insider retains a meaningful position, reducing bearish interpretation.
Background
The article is an SEC Form 4 insider transaction disclosure for Pelthos Therapeutics Inc. (PTHS).
Ticker impact
Pelthos Therapeutics CFO Francis Knuettel II sold 13,947 shares to the issuer, with no 10b5-1 plan disclosed.
Likely limited near-term impact; any move would be small and driven by trading/positioning rather than new fundamentals.
Insider sales can be routine and this filing lacks disclosed transaction price and total value; also it’s a sale to the issuer rather than an open-market sale.
Market effects
Minimal—single-company insider transaction with no stated operational/regulatory/drug-trial update.
None indicated.
None indicated.
Counterpoint
A sale to the issuer could reflect a planned liquidity event or company buyback mechanics, so it may not signal negative outlook.
Key entities
- issuerPelthos Therapeutics Inc.
Company whose CFO reported a Form 4 sale to the issuer of 13,947 shares.
- insiderFrancis Knuettel II
CFO, Treas & Secty; sold shares to the issuer and reported holdings after transaction.
